Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas
OBJECTIVES: I. Determine the response rate to trastuzumab in patients with advanced or
metastatic salivary gland cancer. II. Determine the time to progression in these patients
after this regimen. III. Determine the toxicity of trastuzumab in these patients.
OUTLINE: Patients are stratified according to histology: intercalated duct (adenoid cystic
carcinoma, acinic cell carcinoma, malignant mixed tumor, polymorphous low grade
adenocarcinoma, undifferentiated carcinoma, adenocarcinoma) vs excretory duct (squamous cell
carcinoma, mucoepidermoid carcinoma). Patients receive trastuzumab IV over 30-90 minutes
weekly for 4 weeks. Treatment continues in the absence of disease progression or
unacceptable toxicity. Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 50 patients (25 per stratum) will be accrued for this study.
Interventional
Primary Purpose: Treatment
Marshall R. Posner, MD
Study Chair
Dana-Farber Cancer Institute
United States: Federal Government
CDR0000067405
NCT00004163
January 1999
Name | Location |
---|---|
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Massachusetts General Hospital Cancer Center | Boston, Massachusetts 02114 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Washington University Barnard Cancer Center | Saint Louis, Missouri 63110 |
Lourdes Regional Cancer Center | Binghamton, New York 13905 |
Yale-New Haven Hospital | New Haven, Connecticut 06504 |
Hematology/Oncology Associates | Port Saint Lucie, Florida 34952 |
Cape Cod Health Care | Hyannis, Massachusetts 02601 |
Nantucket Cottage Hospital | Nantucket, Massachusetts 02554 |